Asthma Warning: Overusing Blue Inhalers Could Worsen Condition

Millions relying on blue inhalers for asthma relief are advised to consult their GP following updated guidelines. Research indicates that long-term use of these devices, medically known as short-acting beta2 agonists (SABAs), may exacerbate the condition. NICE now recommends transitioning to combination inhalers that target the root cause of asthma attacks: inflammation.

The traditional blue inhaler, containing salbutamol, has long served as a rescue medication for immediate symptom relief. However, NICE warns that overuse is associated with a higher incidence of severe asthma attacks, hospital admissions, and fatalities. In England, nearly half of blue inhaler users were prescribed more than two during the 2024-2025 period, a figure considered a significant warning sign by specialists.

New treatment plans like AIR (Anti-inflammatory Reliever) and MART (Maintenance and Reliever Therapy) utilize inhalers that combine an inhaled steroid with a long-acting beta2 agonist. These advanced treatments not only provide immediate relief but also address the underlying inflammation, leading to fewer flare-ups and improved long-term respiratory health.

Patients aged 12 and over newly diagnosed or requiring step-up treatment are encouraged to adopt these combination inhalers. Healthcare professionals emphasize that reviewing asthma action plans with a doctor ensures proper inhaler use and optimal lung protection, potentially leading to a symptom-free life.